Evidence map›Paper›PMID 34373852›Full record

ArticlebioRxiv : the preprint server for biology2021

Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity.

Akiko Koide, Tatyana Panchenko, Chan Wang, Sara A Thannickal, Larizbeth A Romero, Kai Wen Teng, Francesca-Zhoufan Li, Padma Akkappedi, Alexis D Corrado, Jessica Caro and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Akiko KoidePerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Tatyana PanchenkoPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Chan WangDepartment of Population Health, New York University Langone Health, New York, NY 10016, U.S.A.
Sara A ThannickalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016.
Larizbeth A RomeroPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Kai Wen TengPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Francesca-Zhoufan LiPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Padma AkkappediPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Alexis D CorradoPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Jessica CaroPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Catherine DiefenbachPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Marie I SamanovicNew York University Langone Vaccine Center and New York University Langone Health, New York, NY 10016, U.S.A.
Mark J MulliganNew York University Langone Vaccine Center and New York University Langone Health, New York, NY 10016, U.S.A.
Takamitsu HattoriPerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.
Kenneth A StaplefordDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016.
Huilin LiDepartment of Population Health, New York University Langone Health, New York, NY 10016, U.S.A.
Shohei KoidePerlmutter Cancer Center, New York University Langone Health, New York, NY 10016, U.S.A.

Funding

Probing RAS-mediated Signaling with Monobody InhibitorsR01CA212608 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHOHEI KOIDE, John P O'Bryan · 2017 to 2026
$5.8M
Molecular mechanisms of SHP2 signaling dissected with designer binding proteinsR01CA194864 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KOIDE, SHOHEI · 2016 to 2020
$1.8M
Rational generation of high-performance recombinant antibodies to post-translational modificationsR21CA246457 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HATTORI, TAKAMITSU · 2020 to 2020
$620k
Accurate prediction of neutralization capacity from deep mining of SARS-CoV-2 serologyR21AI158997 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KOIDE, SHOHEI · 2020 to 2020
$466k
NCI NIH HHS R01 CA194864NCI NIH HHS R01 CA212608NCI NIH HHS R21 CA246457NIAID NIH HHS R21 AI158997
6 · The paper itself

Abstract

Antibody responses serve as the primary protection against SARS-CoV-2 infection through neutralization of viral entry into cells. We have developed a two-dimensional multiplex bead binding assay (2D-MBBA) that quantifies multiple antibody isotypes against multiple antigens from a single measurement. Here, we applied our assay to profile IgG, IgM and IgA levels against the spike antigen, its receptor-binding domain and natural and designed mutants. Machine learning algorithms trained on the 2D-MBBA data substantially improve the prediction of neutralization capacity against the authentic SARS-CoV-2 virus of serum samples of convalescent patients. The algorithms also helped identify a set of antibody isotype-antigen datasets that contributed to the prediction, which included those targeting regions outside the receptor-binding interface of the spike protein. We applied the assay to profile samples from vaccinated, immune-compromised patients, which revealed differences in the antibody profiles between convalescent and vaccinated samples. Our approach can rapidly provide deep antibody profiles and neutralization prediction from essentially a drop of blood without the need of BSL-3 access and provides insights into the nature of neutralizing antibodies. It may be further developed for evaluating neutralizing capacity for new variants and future pathogens.

Indexed as

antibody-antigen interactionantibody profilingantibody quantificationflow cytometryimmunityneutralizing antibody

Identifiers

PMID34373852
PMCPMC8351774

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.